BioMarin asserts patent infringement claims against Dr. Reddy's Laboratories related to powder form of Kuvan®
Clients BioMarin Pharmaceutical Inc.
Jones Day successfully represented BioMarin Pharmaceutical, Inc. in a patent infringement action against Dr. Reddy's Laboratories relating to the defendant's submission of an Abbreviated New Drug Application to the FDA seeking approval of a powder form of generic versions of Kuvan® (sapropterin dihydrocholride), the only FDA-approved treatment to reduce blood phenylalanine levels in persons with BH-4 responsive phenylketonuria (PKU). A settlement was reached and the case dismissed.
BioMarin Pharmaceutical Inc. v. Dr. Reddy's Laboratories, Inc. et al., No. 3-17-cv-00774 (D.N.J.)